None listed
Conditions
Brief summary
This study aims to evaluate biomarkers from blood, tissue, urine, and stool, in order to assess how useful they are in predicting treatment response and side effects from Immunotherapy. Who is it for? You may be eligible to join this study if you are aged 18 years or older and have been diagnosed with non-small cell lung cancer, bladder cancer, or kidney cancer, for which you will be commencing Immunotherapy. Study details This study will involve a taking a variety of biological samples including, blood, urine, stool and tissue on seven separate occasions throughout the 12 month study period. The samples will be used to evaluate new tests (biomarkers) to assess how useful they are in predicting cancer outcomes. It is hoped that these biomarker tests can provide insight to changes in tumour tissue, blood, stool and urine during treatment. The information from this study will be crucial in personalizing Immunotherapy treatment.
Interventions
Participants with advanced non-small cell lung, bladder and kidney cancers who are newly commencing immunotherapy treatment will be recruited. Participants will provide blood samples at regular intervals (baseline, 3 weeks, 6 weeks, 3 months, 6 months and 12 months) and urine/stool samples (baseline, 6 weeks, 6 months)
Sponsors
Ingham Institute for Applied Medical Research
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Histologically or cytologically confirmed non-small cell lung cancer, bladder cancer, kidney cancer Must be commencing immunotherapy for NSCLC, renal or bladder cancer
Exclusion criteria
Not commencing immunotherapy No consent signed
Outcome results
None listed